Market Cap 626.91M
Revenue (ttm) 0.00
Net Income (ttm) -161.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,182,000
Avg Vol 1,596,618
Day's Range N/A - N/A
Shares Out 283.67M
Stochastic %K 43%
Beta 1.18
Analysts Strong Sell
Price Target $3.57

Company Profile

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in SEACRAFT-2 pivotal Phase 3 trial for patients with NRAS-mutated (NRASm) melanoma; and in SEACRAFT-1 Phase 1b trial for patients with NRAS Q61X melanoma. It also develops ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-altered solid tumors; ERA...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 465 6511
Address:
3115 Merryfield Row, Suite 300, San Diego, United States
TheRealShortSqueezy
TheRealShortSqueezy Oct. 16 at 7:15 PM
$ACTU | Redefining the Future of Cancer Therapy 🧬 🔸 Actuate Therapeutics is pioneering advanced therapies to overcome resistance in aggressive and hard-to-treat cancers. 🔸 Its precision approach targets key disease pathways, aiming for more effective and lasting outcomes. 🔸 Lead drug elraglusib has doubled 1-year survival rates in pancreatic cancer and strengthened results when paired with chemotherapy. 📈 🔸 Collaborations with Harvard Medical School, Mass General Brigham, and other top institutions reinforce its clinical and regulatory momentum. 🤝 🔸 With the oncology market set to surpass $500B by 2033, $ACTU is positioned to be a standout innovator driving real-world impact in cancer care. 🎯 The company’s next round of data and corporate news could set the tone for its next big move📈 Communicated Disclaimer: https://chartingdaily.com/Actu Sector Peers: $NVAX $VIR $CRVS $ERAS
2 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 1:44 PM
Stifel has adjusted their stance on Erasca ( $ERAS ), setting the rating to Buy with a target price of 4.
0 · Reply
notreload_ai
notreload_ai Oct. 16 at 1:14 PM
Stifel initiates $ERAS coverage with Buy rating and $4.X target. Analyst sees $1.56B revenue potential for ERAS-0015 cancer treatment despite competition. https://notreload.xyz/erasca-gets-buy-rating-cancer-drug-potential/
0 · Reply
Quantumup
Quantumup Oct. 15 at 8:29 PM
Stifel $RVMD: We are resuming coverage of Revolution Medicines (RVMD) with a Buy rating and $85 target price. $IMRX $ERAS $DAWN $BBOT We believe RVMD is on the cusp of majorly disrupting the PDAC standard of care - we expect other indications to follow in years to come. The TAM is massive, ~30% of all solid tumors have some type of RAS alteration. RVMD's first-in-class pan-RAS is poised to benefit from a substantial first-to-market advantage; nearest competitors are years behind. We model first revenue for RVMD in 1Q27 and global revenue of $11.3B by 2035. Sector specialists are in 2 camps on RVMD: (1) too expensive, or (2) still undervalued for PDAC opportunity alone. We expect that once the 2L PDAC Ph3 reads out in 2026, the game changes as the stock becomes attractive to a more diverse group of investors, and those currently on the sideline would be wise to take a stake sooner.
0 · Reply
QuantInsider
QuantInsider Oct. 12 at 11:16 AM
What’s going on with $ERAS? Saw a big 7,072-contract ask-side sweep in those Jan 16 26 $2 calls on Oct 8 That’s about $842K at 172% IV Huge volume spike But with Morgan Stanley and BofA downgrades pushing it to a 2025 low, the risk is real Feels like early accumulation But I’m holding off Need to see if open interest grows next session and the call bid holds before thinking long Don’t jump the gun unless there’s follow-through in call OI and volume
0 · Reply
itoprag
itoprag Oct. 8 at 9:38 PM
$ERAS 15k shares, in at $1.29 on May 29, out today at $2.71. Not too shabby.
0 · Reply
Molllz_smartmoney
Molllz_smartmoney Oct. 8 at 2:20 PM
👀 $ERAS Update 👀 Contracts are pushing close to 50% gains 💰
0 · Reply
Molllz_smartmoney
Molllz_smartmoney Oct. 7 at 7:18 PM
🔥 $ERAS Jan '26 $2 Calls seeing MASSIVE flow! 📊 Flow Breakdown: Volume: 21,629 contracts Open Interest: 1,157 Avg Premium: $0.84 Total Premium: $1.8M+ 19X volume vs OI ratio! 19% ITM (in the money) That's significant premium flooding into these contracts. Volume nearly 19x open interest—someone's building a serious position or institutions rotating in. Worth watching closely! 👀
0 · Reply
kar3en_macias
kar3en_macias Oct. 3 at 7:25 PM
$ERAS BRO NXXT PRINTS NONSTOP… THIS ISN’T NORMAL 📊
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 3 at 4:38 PM
$ERAS #KRAS landscape. SA doesn't update mc/ev in real-time - ERAS mc is now ~$720 million, cash is ~$350 million. @Night_Owl_Biotech $RVMD $VSTM $ELTX $ARVN
0 · Reply
Latest News on ERAS
Erasca to Present at Upcoming Investor Conferences in June

May 29, 2025, 8:00 AM EDT - 5 months ago

Erasca to Present at Upcoming Investor Conferences in June


Erasca, Inc.: Carving A Different Niche In RAS Signaling

Apr 25, 2025, 11:33 AM EDT - 6 months ago

Erasca, Inc.: Carving A Different Niche In RAS Signaling


Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma

Jan 27, 2025, 12:09 AM EST - 9 months ago

Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma


Erasca to Present at Upcoming Investor Conferences

Nov 5, 2024, 8:00 AM EST - 1 year ago

Erasca to Present at Upcoming Investor Conferences


Erasca: Potential Strong Upside Ahead

Feb 8, 2023, 11:21 AM EST - 2 years ago

Erasca: Potential Strong Upside Ahead


TheRealShortSqueezy
TheRealShortSqueezy Oct. 16 at 7:15 PM
$ACTU | Redefining the Future of Cancer Therapy 🧬 🔸 Actuate Therapeutics is pioneering advanced therapies to overcome resistance in aggressive and hard-to-treat cancers. 🔸 Its precision approach targets key disease pathways, aiming for more effective and lasting outcomes. 🔸 Lead drug elraglusib has doubled 1-year survival rates in pancreatic cancer and strengthened results when paired with chemotherapy. 📈 🔸 Collaborations with Harvard Medical School, Mass General Brigham, and other top institutions reinforce its clinical and regulatory momentum. 🤝 🔸 With the oncology market set to surpass $500B by 2033, $ACTU is positioned to be a standout innovator driving real-world impact in cancer care. 🎯 The company’s next round of data and corporate news could set the tone for its next big move📈 Communicated Disclaimer: https://chartingdaily.com/Actu Sector Peers: $NVAX $VIR $CRVS $ERAS
2 · Reply
JarvisFlow
JarvisFlow Oct. 16 at 1:44 PM
Stifel has adjusted their stance on Erasca ( $ERAS ), setting the rating to Buy with a target price of 4.
0 · Reply
notreload_ai
notreload_ai Oct. 16 at 1:14 PM
Stifel initiates $ERAS coverage with Buy rating and $4.X target. Analyst sees $1.56B revenue potential for ERAS-0015 cancer treatment despite competition. https://notreload.xyz/erasca-gets-buy-rating-cancer-drug-potential/
0 · Reply
Quantumup
Quantumup Oct. 15 at 8:29 PM
Stifel $RVMD: We are resuming coverage of Revolution Medicines (RVMD) with a Buy rating and $85 target price. $IMRX $ERAS $DAWN $BBOT We believe RVMD is on the cusp of majorly disrupting the PDAC standard of care - we expect other indications to follow in years to come. The TAM is massive, ~30% of all solid tumors have some type of RAS alteration. RVMD's first-in-class pan-RAS is poised to benefit from a substantial first-to-market advantage; nearest competitors are years behind. We model first revenue for RVMD in 1Q27 and global revenue of $11.3B by 2035. Sector specialists are in 2 camps on RVMD: (1) too expensive, or (2) still undervalued for PDAC opportunity alone. We expect that once the 2L PDAC Ph3 reads out in 2026, the game changes as the stock becomes attractive to a more diverse group of investors, and those currently on the sideline would be wise to take a stake sooner.
0 · Reply
QuantInsider
QuantInsider Oct. 12 at 11:16 AM
What’s going on with $ERAS? Saw a big 7,072-contract ask-side sweep in those Jan 16 26 $2 calls on Oct 8 That’s about $842K at 172% IV Huge volume spike But with Morgan Stanley and BofA downgrades pushing it to a 2025 low, the risk is real Feels like early accumulation But I’m holding off Need to see if open interest grows next session and the call bid holds before thinking long Don’t jump the gun unless there’s follow-through in call OI and volume
0 · Reply
itoprag
itoprag Oct. 8 at 9:38 PM
$ERAS 15k shares, in at $1.29 on May 29, out today at $2.71. Not too shabby.
0 · Reply
Molllz_smartmoney
Molllz_smartmoney Oct. 8 at 2:20 PM
👀 $ERAS Update 👀 Contracts are pushing close to 50% gains 💰
0 · Reply
Molllz_smartmoney
Molllz_smartmoney Oct. 7 at 7:18 PM
🔥 $ERAS Jan '26 $2 Calls seeing MASSIVE flow! 📊 Flow Breakdown: Volume: 21,629 contracts Open Interest: 1,157 Avg Premium: $0.84 Total Premium: $1.8M+ 19X volume vs OI ratio! 19% ITM (in the money) That's significant premium flooding into these contracts. Volume nearly 19x open interest—someone's building a serious position or institutions rotating in. Worth watching closely! 👀
0 · Reply
kar3en_macias
kar3en_macias Oct. 3 at 7:25 PM
$ERAS BRO NXXT PRINTS NONSTOP… THIS ISN’T NORMAL 📊
0 · Reply
outlawinvestor1
outlawinvestor1 Oct. 3 at 4:38 PM
$ERAS #KRAS landscape. SA doesn't update mc/ev in real-time - ERAS mc is now ~$720 million, cash is ~$350 million. @Night_Owl_Biotech $RVMD $VSTM $ELTX $ARVN
0 · Reply
Christyatmond
Christyatmond Oct. 3 at 2:43 PM
$ERAS wow a china drug is pumping hard by Logos.
1 · Reply
makedatbread88
makedatbread88 Oct. 3 at 2:40 PM
$ERAS I guess everything and anything just goes up nowadays another pretty much 100% runner ***Follow me for more winning calls!***
0 · Reply
Chad_Thunderstock
Chad_Thunderstock Oct. 3 at 8:07 AM
$ERAS 25% runup. Take your exits and don't greedy.
0 · Reply
Whiskey1679
Whiskey1679 Sep. 30 at 8:12 PM
Whiskey's Penny Picks out tomorrow 6:15 am PDT!! See my Pinned Post for 🏆 Winners 🏆!!! AH Gainers: $CJET $JELD $ERAS $NVNI $BENF
0 · Reply
DaBullRunner
DaBullRunner Sep. 30 at 8:03 PM
$ERAS there it goes… ICU is going to make a big run soon 🚨🚨🚨🚨🚨 Here’s why👇
0 · Reply
makedatbread88
makedatbread88 Sep. 30 at 5:39 PM
$ERAS breaking out here ***Follow me for more winning calls!***
1 · Reply
_www_larval_com_
_www_larval_com_ Sep. 30 at 4:27 PM
$ERAS just jumped 6% higher to 7% (~2Mv) a few minutes ago, 10/17 options, follow for more volatility.
0 · Reply
Doozio
Doozio Sep. 27 at 3:57 PM
$ERAS let’s bang bro. It’s 🐒🍌🧠⏰♾️
0 · Reply
Chucky91
Chucky91 Sep. 26 at 10:51 PM
$ERAS is a breakout growth story, combining disruptive innovation, strong execution, and accelerating momentum. With powerful market tailwinds and rising investor interest, the stock is perfectly positioned for significant upside.
0 · Reply
Chad_Thunderstock
Chad_Thunderstock Sep. 26 at 8:20 PM
$ERAS target reached. Thank you all and cheers to those who were patient
1 · Reply
JrNannies
JrNannies Sep. 26 at 5:54 PM
$ERAS cmon $4
0 · Reply
makedatbread88
makedatbread88 Sep. 26 at 5:28 PM
$ERAS this one’s been loaded heavily the last week just broke a major resistance at $2 somethings going on ***Folow me for more winning calls!***
0 · Reply